艾司西酞普兰、帕罗西汀治疗产后抑郁症的临床疗效对比

Comparison of clinical efficacy of escitalopram and paroxetine in the treatment of postpartum depression

目的:分析艾司西酞普兰、帕罗西汀治疗产后抑郁症的临床效果。方法:选取2020年3月-2022年3月于本院治疗的产后抑郁症患者94例为研究对象。随机分为对照组和观察组各47例。对照组采用帕罗西汀治疗,观察组采用艾司西酞普兰治疗。治疗12周后采用汉密尔顿抑郁量表(Hamilton Depression Rating Scale,HAMD)进行评价对比两组的临床疗效、抑郁程度,采用健康调查简表(MOS item short from health survey,SF-36)评分进行评价生活质量对比,并记录对比两组治疗过程中不良反应发生率。结果:观察组临床总有效率为97.92%,明显高于对照组82.98%(P<0.05)。治疗前,两组HAMD评分比较无统计学意义(P>0.05);治疗后,两组HAMD评分均下降,SF-36评分均上升,且观察组HAMD评分均低于对照组,SF-36评分高于对照组(P<0.05)。两组不良反应比较无统计学意义(P>0.05)。结论:艾司西酞普兰与帕罗西汀相比,前者具有较高的临床疗效及安全性,且更有效改善患者抑郁症状及生活质量,值得临床推广应用。

Objective:To analyze the clinical effect of escitalopram and paroxetine in the treatment of postpartum depression.Methods:94 patients with postpartum depression treated in our hospital from March 2020 to March 2022 were selected as the study objects.They were randomly divided into control group and observation group with 47 cases in each group.The control group was treated with paroxetine,and the observation group was treated with escitalopram.12 weeks after treatment by Hamilton Depression Rating Scale(Hamilton'Rating Scale,HAMD)to evaluate compared two groups of clinical curative effect,the degree of Depression,the health survey profile(the MOS item short from health survey,The SF-36 score was used to evaluate the quality of life comparison,and the incidence of adverse reactions during treatment was recorded between the two groups.Results:The total clinical effective rate of observation group was 97.92%,which was significantly higher than that of control group 82.98%(P<0.05).Before treatment,there was no statistical significance in HAMD scores between the two groups(P>0.05).After treatment,HAMD score decreased in both groups,SF-36 score increased in both groups,and HAMD score in observation group was lower than control group,SF-36 score was higher than control group(P<0.05).There was no statistical significance in adverse reactions between the two groups(P>0.05).Conclusion:Compared with paroxetine,escitalopram has higher clinical efficacy and safety,and can effectively improve patients'depressive symptoms and quality of life,which is worthy of clinical promotion and application.